Lipocine Inc reports results for the quarter ended in September 30 - Earnings Summary

Lipocine

07/11/2024 17:20

* Lipocine Inc  LPCN.OQ  reported a quarterly adjusted loss
of 41
cents​​ per share for the quarter ended September 30, higher
than the same quarter last year, when the company reported EPS
of $-1.27.  The mean expectation of two analysts for the quarter
was for a loss of 48 cents per share. Wall Street expected
results to range from -59 cents to -38 cents per share.
    * Reported revenue was zero​; analysts expected $151.00
thousand. 
    * Lipocine Inc's reported EPS for the quarter was a loss
of 41
cents​.
    * The company reported a quarterly loss of $2.22 million.
    * Lipocine Inc shares had risen by 35.0% this quarter and
gained 117.2% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 31.1%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is  "buy."

Wall Street's median 12-month price target for Lipocine Inc is
$21.50 
This summary was machine generated from LSEG data November 7 at
05:20 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.48          -0.41          Beat
 Jun. 30 2024      -0.78          -0.57          Beat
 Mar. 31 2024      -0.68          0.66           Beat
 Dec. 31 2023      -0.47          -0.42          Beat